August 2026

This commentary will appear in the August issue of Evidence-Based Oncology.

How tebentafusp, a BiTE bispecific T-cell engager, changes metastatic uveal melanoma care—HLA testing, dosing, safety and access tips for clinics.

The needs of the nation's 63 million caregivers are rising on the public policy agenda, as bipartisan bills appear in the Congress to offer tax credits and other support.

Experts discussed innovations in oncology care, treatment access, pharmacy workflows, and patient outcomes.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

This discussion will appear in the August issue of Evidence-Based Oncology.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Our August cover story from Evidence-Based Oncology.

Coverage from the Institute for Value-Based Medicine session in Dallas, Texas, held May 21,2026.

FDA clears hands-free on-body injector for isatuximab in multiple myeloma, cutting treatment time and reactions while matching IV efficacy.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.

As CAR T-cell therapy expands into outpatient and community settings, Reimagine Care and The Center for Cancer and Blood Disorders are creating a monitoring infrastructure to support patients and caregivers alike.

Community Oncology Alliance AI Playbook powers digital health practice transformation, guiding teams to choose AI partners, protect data, and expand efficient care.

As SYMPATICO publishes final data for ibrutinib–venetoclax relapsed mantle cell lymphoma, a new commentary discusses how combinations with zanubrutinib and sonrotoclax-era could take over.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

The FDA approved sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for metastatic triple-negative breast cancer.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Cardinal Health hires ex-FCS leader Nathan Walcker to drive The Specialty Alliance's growth, including managed services in gastroenterology and urology.